At the time of writing, Xeris Biopharma Holdings Inc [XERS] stock is trading at $7.87, down -0.76%. An important factor to consider is whether the stock is rising or falling in short-term value. The XERS shares have gain 11.00% over the last week, with a monthly amount glided 13.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xeris Biopharma Holdings Inc [NASDAQ: XERS] stock has seen the most recent analyst activity on December 09, 2025, when Barclays initiated its Overweight rating and assigned the stock a price target of $9. On November 11, 2024, downgrade downgraded it’s rating to Neutral but maintained its price target of $3 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $5 on March 28, 2024. Craig Hallum initiated its recommendation with a Buy and recommended $4.50 as its price target on August 28, 2023. Jefferies started tracking with a Buy rating for this stock on October 21, 2022, and assigned it a price target of $4. In a note dated April 28, 2022, Craig Hallum initiated a Buy rating and provided a target price of $6.50 on this stock.
For the past year, the stock price of Xeris Biopharma Holdings Inc fluctuated between $3.14 and $10.08. Currently, Wall Street analysts expect the stock to reach $13.5 within the next 12 months. Xeris Biopharma Holdings Inc [NASDAQ: XERS] shares were valued at $7.87 at the most recent close of the market. An investor can expect a potential return of 71.54% based on the average XERS price forecast.
Analyzing the XERS fundamentals
According to Xeris Biopharma Holdings Inc [NASDAQ:XERS], the company’s sales were 266.14M for trailing twelve months, which represents an 37.06% jump. Gross Profit Margin for this corporation currently stands at 0.84% with Operating Profit Margin at 0.04%, Pretax Profit Margin comes in at -0.06%, and Net Profit Margin reading is -0.06%. To continue investigating profitability, this company’s Return on Assets is posted at -0.04, Equity is 0.74 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -44.35.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Xeris Biopharma Holdings Inc [NASDAQ:XERS] has a current ratio of 1.93. On the other hand, the Quick Ratio is 1.35, and the Cash Ratio is 0.79. Considering the valuation of this stock, the price to sales ratio is 4.91.
Transactions by insiders
Recent insider trading involved McCulloch Kevin, that happened on Jan 08 ’26 when 15000.0 shares were sold. Officer, KEVIN MCCULLOCH completed a deal on Jan 08 ’26 to buy 60000.0 shares. Meanwhile, Shannon John Patrick Jr sold 24907.0 shares on Jan 05 ’26.
